SCHEMBL653131

SCHEMBL653131

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc2c(c1)CCO2)Cc1ccc2c(c1)OCCO2

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.59
KCNH2 Q12809 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GBA1 P04062 1/20 0.35
CHRM5 P08912 3/20 0.35
CHRM1 P11229 3/20 0.35
TSHR P16473 1/20 0.35
CXCR3 P49682 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM3 P20309 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648190 0.97 C5AR1 (0.65) C5AR1KCNH2SMN1; SMN2LMNAL3MBTL1
SCHEMBL5136874 0.95 C5AR1 (0.54) C5AR1KCNH2CHRM5CHRM1TSHR
SCHEMBL1912839 0.94 C5AR1 (0.66) C5AR1SMN1; SMN2LMNAL3MBTL1GBA1
SCHEMBL5134570 0.92 C5AR1 (0.54) C5AR1KCNH2CHRM5CHRM1TSHR
SCHEMBL4765639 0.92 C5AR1 (0.64) C5AR1SMN1; SMN2LMNAL3MBTL1GBA1
SCHEMBL1915326 0.92 C5AR1 (0.51) C5AR1KCNH2CHRM5CHRM1TSHR
SCHEMBL649388 0.92 C5AR1 (0.53) C5AR1KCNH2SMN1; SMN2LMNAL3MBTL1
SCHEMBL649255 0.91 C5AR1 (0.71) C5AR1SMN1; SMN2LMNAL3MBTL1GBA1
SCHEMBL5135701 0.90 C5AR1 (0.64) C5AR1SMN1; SMN2LMNAL3MBTL1GBA1
SCHEMBL1913012 0.90 C5AR1 (0.50) C5AR1KCNH2CHRM5CHRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed